A regulatory requirement non-interventional study to monitor the safety and effectiveness of Spesolimab in Korean patients with flares with generalized pustular psoriasisFirst published 24/07/2024 Last updated 24/07/2024 EU PAS number: EUPAS1000000278StudyPlanned